[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649674":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":35,"centralContacts":40,"locations":45,"responsibleParty":63,"collaborators":66,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":29,"eligibilityCriteria":74,"healthyVolunteers":70,"sex":75,"minAge":76,"maxAge":29,"enrollmentInfo":77,"targetDuration":29,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":29,"overallStatus":87,"whyStopped":29,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Barbara Ann Karmanos Cancer Institute","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"[18F]FETrp PET\u002FCT in newly diagnosed grade 4 glioma prior to radiation","EXPERIMENTAL","Arm 1. \\[18F\\]FETrp PET prior to radiotherapy in newly diagnosed grade 4 glioblastoma to provide a better treatment target volume",[13],"Diagnostic Test: [18F]FETrp PET\u002FCT",{"label":15,"type":10,"description":16,"interventionNames":17},"[18F]FETrp PET\u002FCT in previously treated gliomas with post radiation progression","Arm 2. \\[18F\\]FETrp PET to differentiate post-treatment glioma progression from radiation-induced MRI changes",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"[18F]FETrp PET\u002FCT pre and post Minocycline 200mg\u002Fday","Arm 3. Minocycline orally 200mg\u002Fday administered between the first \\[18F\\]FETrp PET scan and the month follow up \\[18F\\]FETrp scan to determine if pharmacologic inhibition of the kynurenine pathway will reduce tumoral tryptophan metabolic rates in low-grade gliomas",[22,13],"Drug: Minocycline 200mg\u002Fday",[24,30],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"DRUG","Minocycline 200mg\u002Fday","Minocycline 200mg orally daily to start within 14 days of the first \\[18F\\]FETrp PET\u002FCT and taken until the second \\[18F\\]FETrp PET\u002FCT obtained 25-44 days after the start of the Minocycline in Arm 3",[19],null,{"type":31,"name":32,"description":33,"armGroupLabels":34,"otherNames":29},"DIAGNOSTIC_TEST","[18F]FETrp PET\u002FCT","\\[18F\\]FETrp PET\u002FCT used in all three arms",[9,15,19],[36],{"name":37,"affiliation":38,"role":39},"Csaba Juhasz, M.D.,Ph.D.","Wayne State University","PRINCIPAL_INVESTIGATOR",[41],{"name":37,"role":42,"phone":43,"phoneExt":29,"email":44},"CONTACT","313-966-5136","csaba.juhasz@wayne.edu",[46],{"facility":47,"status":29,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Karmanos Cancer Institute","Detroit","Michigan","48201","United States","US",{"type":54,"coordinates":55},"Point",[56,57],-83.04575,42.33143,{"lat":57,"lon":56},[60],{"name":61,"role":42,"phone":62,"phoneExt":29,"email":29},"Csaba Juhasz, M.D., Ph.D","1-800-527-6266",{"type":39,"investigatorFullName":64,"investigatorTitle":65,"investigatorAffiliation":5,"oldNameTitle":29,"oldOrganization":29},"Csaba Juhasz","Principal Investigator",[67],{"name":38,"class":6},"100649674","phase-2-positron-emission-tomographycomputed-tomography-petct-imaging-in-patients-diagnosed-with-a-glioma-100649674",false,"NCT07735819","Positron Emission Tomography\u002FComputed Tomography (PET\u002FCT) Imaging in Patients Diagnosed With a Glioma","Tryptophan-kynurenine Pathway PET Imaging in Human Gliomas","FOR ARMS 1-3\n\nInclusion Criteria:\n\n* Age =18 years.\n* Patient is able to lie in the PET\u002FCT scanner for at least 60 minutes while undergoing scanning.\n* Patient is willing and able to review, understand, and provide written consent for the study procedures and indicates that they are aware of the investigational nature of this study.\n\nExclusion Criteria:\n\n* Patients who are pregnant or lactating are excluded. Premenopausal women (defined per institutional guidelines) must have a negative pregnancy test (urine or serum) within 7 days of the PET scan.\n* Severe increased intracranial pressure, status epilepticus, or other severe or progressing clinical symptoms requiring urgent intervention in the opinion of the treating\n* Karnofsky performance score \\\u003C60, as determined by one of the clinician co- investigators.\n\nADDITIONAL CRITERIA FOR ARM 1:\n\nInclusion Criteria:\n\n* Histopathology\u002Fcytopathological diagnosis of a glioblastoma without a history of radiation.\n* The tumor is deemed amenable for radiation treatment (pre-radiation planning MRI can be done before or after the PET scan).\n\nADDITIONAL CRITERIA FOR ARM 2:\n\nInclusion Criteria:\n\n* Previous histopathology\u002Fcytopathological diagnosis of glioblastoma.\n* History of glioma radiation.\n* Presence of a new or progressing enhancing brain lesion on follow-up clinical MRI suspicious for post-radiation glioma progression or late radiation-induced MRI changes (i.e., radiation injury), at least 7 mm in bidirectional diameter.\n* The most recent MRI, used for comparison with the PET\u002FCT, is performed within 4 weeks of the planned PET scan.\n\nADDITIONAL CRITERIA FOR ARM 3\n\nInclusion Criteria:\n\n* MRI diagnosis of a brain tumor, previously verified to be a low-grade (WHO grade 2, IDH (isocitrate dehydrogenase) mutant glioma, based on histopathology from biopsy or resection.\n* The detected mass on the most recent clinical MRI is at least 7 mm in bidirectional diameter (i.e., twice the PET scanner resolution).\n* The tumor does not require urgent (within 1 month) resection, steroid treatment, or radiation.\n* The most recent MRI, used for comparison with the PET\u002FCT, is performed within 4 weeks.\n* Patient agrees to have a baseline and follow-up PET\u002FCT scan (approximately 1 month later) and interval oral treatment with 200mg\u002Fday minocycline.\n* Due to planned minocycline treatment, patients will need to have adequate renal function\n\nExclusion Criteria:\n\n* Active connective tissue disorders, such as lupus or scleroderma.\n* History of allergic reaction to minocycline or any tetracyclines.\n* Ongoing treatment with warfarin with INR \\> 1.5.\n* History of colitis during antibiotics treatment.","ALL","18 Years",{"count":78,"type":79},61,"ESTIMATED","INTERVENTIONAL",[82],"PHASE2","The goal of this clinical trial is to evaluate Positron emission tomography\u002Fcomputed tomography (PET\u002FCT) imaging with the radiotracer 1-(2-\\[18F\\]fluoroethyl)-l-tryptophan (\\[18F\\]FETrp) in patients diagnosed with a glioma. This study has 3 aims:\n\n* to assess if the \\[18F\\]FETrp PET\u002FCT can outperform Magnetic Resonance Imaging (MRI) by providing a better treatment target volume in newly diagnosed Stage 4 glioma patients\n* better differentiate tumor progression from radiation induced MRI changes in post treatment stage 4 gliomas\n* by giving a drug that can inhibit a pathway to allow objective assessment of treatment effects in low grade gliomas",[85,86],"Low Grade Glioma","Glioblastoma","NOT_YET_RECRUITING","2026-07-24",{"date":90,"type":91},"2026-07-30","ACTUAL",{"date":93,"type":79},"2026-09",{"date":95,"type":79},"2031-06-30",{"name":5,"class":6},1]